EA201300647A1 - Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц - Google Patents

Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц

Info

Publication number
EA201300647A1
EA201300647A1 EA201300647A EA201300647A EA201300647A1 EA 201300647 A1 EA201300647 A1 EA 201300647A1 EA 201300647 A EA201300647 A EA 201300647A EA 201300647 A EA201300647 A EA 201300647A EA 201300647 A1 EA201300647 A1 EA 201300647A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pure
nonpolymorphic
acids
particle size
crystalline yellow
Prior art date
Application number
EA201300647A
Other languages
English (en)
Other versions
EA025586B1 (ru
Inventor
Рудольф Вильгельм
Маркус Прёльс
Эрик Фишер
Хейди Ванерлюнд Паулсен
Original Assignee
Др. Фальк Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Фальк Фарма Гмбх filed Critical Др. Фальк Фарма Гмбх
Publication of EA201300647A1 publication Critical patent/EA201300647A1/ru
Publication of EA025586B1 publication Critical patent/EA025586B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

Изобретение относится к чистой полиморфной модификации нор-УДХК или бис-нор-УДХК или их фармацевтически приемлемой соли. Изобретение дополнительно предлагает фармацевтическую композицию, содержащую полиморфную модификацию изобретения и способ получения полиморфной модификации. Изобретение включает фармацевтическое применение полиморфной модификации или фармацевтической композиции изобретения.
EA201300647A 2010-11-30 2011-11-30 Оптимизированный синтез чистых, неполиморфных кристаллических жёлчных кислот с заданным размером частиц EA025586B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193143A EP2468762A1 (en) 2010-11-30 2010-11-30 Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
PCT/EP2011/071406 WO2012072689A1 (en) 2010-11-30 2011-11-30 Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Publications (2)

Publication Number Publication Date
EA201300647A1 true EA201300647A1 (ru) 2014-01-30
EA025586B1 EA025586B1 (ru) 2017-01-30

Family

ID=44275998

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300647A EA025586B1 (ru) 2010-11-30 2011-11-30 Оптимизированный синтез чистых, неполиморфных кристаллических жёлчных кислот с заданным размером частиц

Country Status (24)

Country Link
US (2) US9512167B2 (ru)
EP (2) EP2468762A1 (ru)
JP (2) JP6276592B2 (ru)
CN (1) CN103298825B (ru)
AU (1) AU2011334928B2 (ru)
CA (1) CA2818984C (ru)
CY (1) CY1118036T1 (ru)
DK (1) DK2646457T3 (ru)
EA (1) EA025586B1 (ru)
ES (1) ES2597652T3 (ru)
HK (1) HK1187351A1 (ru)
HR (1) HRP20161187T1 (ru)
HU (1) HUE029847T2 (ru)
IL (1) IL226616A (ru)
LT (1) LT2646457T (ru)
ME (1) ME02480B (ru)
NZ (2) NZ610862A (ru)
PL (1) PL2646457T3 (ru)
PT (1) PT2646457T (ru)
RS (1) RS55211B1 (ru)
SI (1) SI2646457T1 (ru)
UA (1) UA112764C2 (ru)
WO (1) WO2012072689A1 (ru)
ZA (1) ZA201303820B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
US20200024299A1 (en) * 2016-09-30 2020-01-23 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
EP3461485A1 (en) 2017-09-28 2019-04-03 Dr. Falk Pharma Gmbh Use of nor-ursodeoxycholic acid for reducing liver fat
WO2021130232A1 (en) 2019-12-23 2021-07-01 Medizinische Universität Wien Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
WO2024023669A1 (en) * 2022-07-25 2024-02-01 Shilpa Medicare Limited Pharmaceutical compositions of nor-udca

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289020B (ru) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
ITMI20012572A1 (it) 2001-12-06 2003-06-06 Istituto Biochimico Italiano Microgranuli di acido ursodesossicolico
HUE030010T2 (en) * 2005-05-12 2017-04-28 Medizinische Universität Graz 24-norUDCA for the treatment of autoimmune hepatitis
CN100513415C (zh) * 2005-08-03 2009-07-15 中国人民解放军军事医学科学院毒物药物研究所 胆汁酸衍生物及其医药用途
US20100311708A1 (en) 2007-07-25 2010-12-09 Tarek Moustafa Use of nor-bile acids in the treatment of arteriosclerosis
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Also Published As

Publication number Publication date
WO2012072689A1 (en) 2012-06-07
EA025586B1 (ru) 2017-01-30
ME02480B (me) 2017-02-20
CN103298825B (zh) 2016-11-23
JP2017081989A (ja) 2017-05-18
RS55211B1 (sr) 2017-02-28
JP6276592B2 (ja) 2018-02-07
DK2646457T3 (en) 2016-10-10
NZ708988A (en) 2016-08-26
US10000526B2 (en) 2018-06-19
LT2646457T (lt) 2016-10-10
ES2597652T3 (es) 2017-01-19
CA2818984C (en) 2019-01-08
SI2646457T1 (sl) 2016-10-28
HUE029847T2 (en) 2017-04-28
US20140050791A1 (en) 2014-02-20
US20170057990A1 (en) 2017-03-02
EP2646457B1 (en) 2016-08-17
IL226616A (en) 2017-05-29
AU2011334928A1 (en) 2013-06-20
BR112013013179A2 (pt) 2016-09-06
AU2011334928B2 (en) 2016-09-01
EP2468762A1 (en) 2012-06-27
CY1118036T1 (el) 2017-05-17
PL2646457T3 (pl) 2017-02-28
JP6594917B2 (ja) 2019-10-23
HK1187351A1 (zh) 2014-04-04
NZ610862A (en) 2015-07-31
EP2646457A1 (en) 2013-10-09
CA2818984A1 (en) 2012-06-07
PT2646457T (pt) 2016-10-18
JP2013544267A (ja) 2013-12-12
ZA201303820B (en) 2014-02-26
UA112764C2 (uk) 2016-10-25
HRP20161187T1 (hr) 2016-11-04
US9512167B2 (en) 2016-12-06
CN103298825A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
IN2014MN02106A (ru)
UA110354C2 (ru) Противовирусные соединения
EP3699176A3 (en) Antiviral compounds
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
IN2014KN00948A (ru)
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
IN2012DN03182A (ru)
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MX2012010859A (es) Formas polimorficas st-246 y metodos de preparacion.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
MX2011007978A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2010003213A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
WO2010079045A3 (en) Crystalline salt forms of flibanserine
IN2013DN02555A (ru)
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.